May 07, 2026 | Read online

Checking-in Early: See Why (NSRX) Just Popped On To Our Screen

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

Market Maven Puts the Spotlight on Nasus Pharma Ltd. (NYSE American: NSRX) This Morning—Thursday, May 7, 2026

Don’t miss the next breakout — get real-time alerts sent straight to your phone!

Full Coverage Starts Right Now.

Get (NSRX) On Your Radar While It’s Still Early…

May 7, 2026

Checking-in Early: See Why (NSRX) Just Popped On To Our Screen

Dear Reader,

What if the next major leap in emergency medicine isn’t a new injector, but a way to eliminate the needle altogether?

That’s the shift beginning to emerge inside the growing market for fast-acting, needle-free emergency therapies, where speed, portability, and ease of use are becoming increasingly important during critical medical situations.

One company now pushing directly into that space is Nasus Pharma Ltd. (NYSE American: NSRX), a clinical-stage biotech focused on developing intranasal powder-based treatments for acute emergency conditions.

Its lead candidate, NS002, is designed as a needle-free intranasal epinephrine treatment for anaphylaxis, a market currently dominated by injectable products like EpiPen®. But recent clinical data suggests NS002 may be capable of delivering epinephrine faster than traditional autoinjectors.

And that’s exactly why (NSRX) just hit our radar and is topping our watchlist this morning—Thursday, May 7, 2026.

On March 16, 2026, Nasus reported positive Phase 2 topline results showing NS002 achieved the critical therapeutic epinephrine threshold in a median of just 1.69 minutes versus 3.42 minutes for EpiPen® (p=0.033).

Additional data showed:

• 67.4% of NS002 patients reached therapeutic levels within 2.5 minutes versus 27.1% for EpiPen®
• 88.4% reached the threshold within 5 minutes compared to 64.6% for EpiPen®
• Total epinephrine exposure during the critical first 10 minutes was approximately 50% higher with NS002

Earlier interim Phase 2 data also demonstrated:

• 91% of participants reached the therapeutic plasma threshold at 5 minutes with NS002 versus 67% with EpiPen®
• Peak concentration (Tmax) was reached in 10.8 minutes versus 15 minutes for EpiPen®

Following the positive data, the company announced plans to initiate its pivotal study in Q4 2026, with a targeted readout expected in Q1 2027.

Wall Street analysts have also started assigning aggressive upside targets.

Citizens JMP maintained an Outperform rating and recently adjusted its target from $19 to $18 per share while continuing to highlight NS002’s “best-in-class potential.”

Meanwhile, consensus analyst targets tracked by MarketBeat currently sit around $18 per share, implying upside potential of more than 450%–550% from recent levels near $3.

At the same time, the company’s market structure remains extremely small.

(NSRX) recently moved with a market capitalization near $32M, while continuing to maintain a tightly constrained float structure that can amplify volatility when momentum begins building.

Nasus also strengthened its balance sheet earlier this year, raising approximately $15M in February 2026, which management says is expected to fund operations through the planned NS002 pivotal study and potential NDA submission process.

When you connect the pieces together, it becomes easier to understand why (NSRX) is beginning to stand out.

Positive Phase 2 clinical results. Faster epinephrine delivery versus EpiPen®. Upcoming pivotal trial milestones. Expanding analyst coverage. A tiny market cap. And a needle-free platform targeting acute emergency medicine.

That’s the type of combination that tends to keep emerging biotech names firmly on the radar as new potential catalysts approach.

Nasus Pharma Ltd. (NYSE American: NSRX)

Nasus Pharma Ltd., (NSRX) is a clinical-stage biotechnology company focused on developing needle-free intranasal powder therapies for emergency medical situations. The company’s proprietary dry-powder nasal delivery platform is designed to provide fast absorption, portability, and ease of administration during acute treatment scenarios where every second matters.

Its lead product candidate, NS002, is being developed as an intranasal epinephrine treatment for severe allergic reactions and anaphylaxis. Recent Phase 2 data demonstrated that NS002 achieved therapeutic epinephrine levels faster than EpiPen®, supporting the company’s goal of creating a rapid, non-invasive alternative to traditional injectable emergency treatments.

Beyond NS002, Nasus is advancing a broader intranasal platform aimed at improving dr-ug delivery across emergency and rescue-care applications. The company plans to initiate a pivotal study for NS002 in Q4 2026 as it works toward potential regulatory submission.

Breaking Down the Needle-Free Emergency Treatment Market

Nasus Pharma Ltd. (NYSE American: NSRX) operates within the broader emergency medicine and non-invasive dr-ug delivery sector, a market seeing increased attention as healthcare systems push toward faster, easier-to-administer therapies outside of traditional injectable formats.

One major driver is the global anaphylaxis treatment market itself. According to Grand View Research, the global anaphylaxis market was valued at approximately $2.3B in 2024 and is projected to continue expanding as allergy prevalence rises worldwide. Epinephrine remains the frontline treatment standard, but current delivery methods still rely heavily on autoinjectors like EpiPen®.

At the same time, adoption trends are beginning to shift toward needle-free and intranasal delivery technologies.

Fortune Business Insights estimates the global needle-free dr-ug delivery market could grow from roughly $15B in 2024 to more than $32B by 2032, representing a projected CAGR above 10%. Key growth drivers include patient preference, ease of administration, portability, and faster emergency response capabilities.

The intranasal dr-ug delivery segment specifically has also become an increasingly active area across biotech and pharmaceutical development. MarketsandMarkets projects the global nasal dr-ug delivery market could surpass $98B by 2030, fueled by rising demand for rapid-onset therapies and non-invasive treatment alternatives.

That trend is especially relevant in emergency-use cases.

This is where companies like (NSRX) are attempting to differentiate themselves.

Rather than competing solely on the dr-ug itself, Nasus is focused on improving how emergency medication is delivered. Its proprietary dry-powder intranasal platform is designed to combine portability with rapid absorption, while eliminating the need for injections altogether.

As regulatory agencies and healthcare systems continue prioritizing patient-friendly emergency treatments, the broader sector surrounding needle-free rescue therapies appears positioned for continued expansion over the coming years.

Recent Milestones Driving Momentum at (NSRX)

• Positive Phase 2 Data for NS002: On March 16, 2026, Nasus reported positive Phase 2 topline data showing NS002 reached therapeutic epinephrine levels in 1.69 minutes versus 3.42 minutes for EpiPen®.

• Faster Early Absorption Demonstrated: 67.4% of NS002 patients reached therapeutic levels within 2.5 minutes compared to 27.1% for EpiPen®.

• Pivotal Study Planned: The company plans to launch its pivotal NS002 study in Q4 2026 with potential readout targeted for Q1 2027.

• Pipeline Expansion Underway: Nasus is also advancing additional intranasal programs targeting nausea, vomiting, and metabolic disorders.

• Balance Sheet Strengthened: Management stated recent financing activity is expected to fund operations through the planned pivotal study and potential NDA process.

7 Reasons Why (NSRX) Is Topping Our Watchlist This Morning
—Thursday, May 7, 2026

Positive Phase 2 Clinical Data: (NSRX) recently reported Phase 2 results showing NS002 reached therapeutic epinephrine levels in 1.69 minutes versus 3.42 minutes for EpiPen®.
Needle-Free Emergency Treatment Platform: The company is developing intranasal powder therapies designed to eliminate injections during emergency allergic reactions.
Massive Addressable Market: (NSRX) is targeting the growing global anaphylaxis and needle-free dr-ug delivery markets, sectors projected to reach multi-bn-dollar valuations over the coming years.
Pivotal Trial Approaching: Management plans to initiate the pivotal NS002 study in Q4 2026 with a potential readout expected in Q1 2027.
Analyst Targets Remain Aggressive: Recent analyst price targets ranging from $18–$22 imply substantial upside from current levels near $3.
Small Market Cap + Tight Float: With a market cap near $30M and a tightly structured float, shifts in momentum can create amplified volatility.
Expanding Intranasal Pipeline: Beyond NS002, the company is advancing additional intranasal programs targeting nausea, vomiting, and metabolic disorders.

Take A Look At (NSRX) While It’s Still Early…

When you put the pieces together, it becomes easier to understand why (NSRX) is starting to move onto more biotech watchlists. Positive Phase 2 data, faster epinephrine delivery versus EpiPen®, upcoming pivotal trial plans, and analyst targets ranging from $18–$22 have all helped increase visibility around the story.

At the same time, (NSRX) remains a tightly structured small-cap company operating inside the expanding needle-free emergency treatment market, a sector seeing growing demand for faster, easier-to-administer therapies.

With management targeting a pivotal NS002 study launch in Q4 2026, recent financing in place, and additional intranasal pipeline programs advancing behind the scenes, multiple layers of the story are beginning to align simultaneously.

Also, keep a lookout for my next update.

Sincerely,
Tate Remington
Chief Editor, Market Maven Insights

^{MarketMavenInsights.com}^{(“MarketMavenInsights” or “MMI”) is owned by Source Coastal Media LLC, a multi member limited liability company. Data is provided from third-party sources and MMI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MMI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors.}

^{Pursuant to an agreement between Source Coastal Media LLC and TD Media LLC, Source Coastal Media LLC has been hired for a period beginning on 05/06/2026 and ending on 05/07/2026 to publicly disseminate information about (NSRX:US) via digital communications. Under this agreement, TD Media LLC has paid Source Coastal Media LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Source Coastal Media LLC has been paid fifteen thousand USD (“Funds”). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

^{Neither Source Coastal Media LLC, TD Media LLC and their member own shares of (NSRX:US).}

^{Please see important disclosure information here:}^{https://marketmaveninsights.com/disclosure/nsrx-r4I6W/#details}